Campath (Alemtuzumab) - FDA Alerts

FDA Alerts related to Campath (Alemtuzumab)

FDA ALERT [11/2005]

Three patients in a clinical study of the drug Campath for the treatment of Multiple Sclerosis (MS) developed severe idiopathic thrombocytopenic purpura (ITP). One of the patients died.

ITP happens when the body attacks and kills its own blood platelets. Platelets are a type of blood cell that controls bleeding. Bruising and bleeding may be warning signs of ITP.

Campath is not approved to treat MS. Campath is only approved for treating a form of blood cancer called B-cell chronic lymphocytic leukemia (B-CLL). The label for Campath has a warning about serious and rare blood problems that may happen with the use of this medicine.

Talk to your healthcare professional if you have concerns about taking Campath.